Table 1.
Effect of bezafibrate (BF) on CA in human peripheral lymphocytes for 24- and 48-h treatment periods
| Test substance | Treatment | Structural CA | Percentage of cells with aberrations ± SE | CA/cell ± SE | ||
|---|---|---|---|---|---|---|
| Time (h) | Conc. (µg/mL) | Chromatid type | Chromosome type | |||
| N. Control | – | – | 6 | – | 3.00 ± 0.40c* | 0.03 ± 0.004c* |
| DMSO | 24 | 25 µL | 5 | 1 | 4.50 ± 0.64 | 0.04 ± 0.006 |
| MMC | 24 | 0.20 | 46 | 14 | 25.75 ± 2.02 | 0.33 ± 0.035 |
| BF | 24 | 100 | 5 | 1 | 4.75 ± 0.47a1c3 | 0.05 ± 0.004a1c3 |
| BF | 24 | 175 | 4 | – | 5.00 ± 0.57a1c3 | 0.05 ± 0.005a1c3 |
| BF | 24 | 250 | 7 | – | 4.25 ± 0.94c3 | 0.04 ± 0.009c3 |
| BF | 24 | 325 | 5 | – | 4.75 ± 0.62c3 | 0.04 ± 0.006c3 |
| DMSO | 48 | 25 µL | 6 | 3 | 4.75 ± 0.47 | 0.05 ± 0.004 |
| MMC | 48 | 0.20 | 66 | 29 | 35.50 ± 1.76 | 0.44 ± 0.019 |
| BF | 48 | 100 | 7 | – | 4.75 ± 0.25a2c3 | 0.04 ± 0.002a2c3 |
| BF | 48 | 175 | 5 | 1 | 4.75 ± 0.25a2c3 | 0.04 ± 0.002a2c3 |
| BF | 48 | 250 | 5 | 1 | 5.00 ± 0.40a1c3 | 0.05 ± 0.004a1c3 |
| BF | 48 | 325 | 8 | – | 4.50 ± 0.50c3 | 0.04 ± 0.007c3 |
Data are expressed as the mean values (±SE) obtained from four donors; n = 4
a Significantly different from negative control, b significantly different from solvent control, c significantly different from positive control, c* Positive control significantly different from negative control for 48-h
a1b1c1 p < 0.05; a2b2c2 p < 0.01; a3b3c3 p < 0.001